RGNX
REGENXBIO Inc. NASDAQ Listed Sep 17, 2015$10.42
After hrs
$10.04
-0.40%
Mkt Cap $537.9M
52w Low $6.89
38.0% of range
52w High $16.19
50d MA $8.86
200d MA $10.55
P/E (TTM)
-2.4x
EV/EBITDA
-6.7x
P/B
4.6x
Debt/Equity
2.5x
ROE
-188.7%
P/FCF
-5.9x
RSI (14)
—
ATR (14)
—
Beta
1.13
50d MA
$8.86
200d MA
$10.55
Avg Volume
833.4K
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
9804 Medical Center Drive · Rockville, MD 20850 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | AMC | -1.01 | -1.30 | -28.7% | 8.72 | -3.0% | -0.8% | +20.0% | -4.6% | -5.3% | -3.2% | — |
| Nov 6, 2025 | AMC | -1.38 | -1.20 | +13.0% | 11.17 | -1.5% | +0.4% | -1.7% | +4.8% | +0.4% | +0.3% | — |
| Aug 7, 2025 | AMC | -1.13 | -1.38 | -22.1% | 7.90 | -1.0% | -0.6% | -5.0% | +8.6% | +10.2% | +1.5% | — |
| May 12, 2025 | AMC | 0.41 | 0.12 | -70.7% | 7.97 | +0.0% | +2.6% | +1.8% | +3.7% | +2.9% | +10.1% | — |
| Mar 13, 2025 | AMC | -1.27 | -1.01 | +20.5% | 6.55 | +7.9% | +2.6% | +4.2% | +11.4% | +9.0% | -1.6% | — |
| Nov 6, 2024 | AMC | -1.16 | -1.17 | -0.9% | 9.43 | +8.2% | +18.7% | -0.3% | +3.6% | -9.3% | +1.7% | — |
| Aug 1, 2024 | AMC | -1.29 | -1.05 | +18.6% | 13.31 | -7.4% | -2.0% | -4.1% | +1.4% | -5.1% | -1.2% | — |
| May 8, 2024 | AMC | -1.28 | -1.38 | -7.8% | 16.67 | -0.7% | -5.9% | -1.5% | +1.9% | +0.4% | +2.7% | — |
| Feb 27, 2024 | AMC | -1.27 | -1.43 | -12.6% | 20.02 | -5.0% | -0.6% | -12.4% | +21.5% | +0.8% | +15.2% | — |
| Nov 8, 2023 | AMC | -1.44 | -1.41 | +2.1% | 16.41 | +3.8% | +2.4% | +6.1% | -0.6% | +7.4% | +0.5% | — |
| Aug 2, 2023 | AMC | -1.26 | -1.66 | -31.7% | 18.90 | -7.2% | -7.5% | +1.3% | -0.8% | +1.7% | +1.4% | — |
| May 3, 2023 | AMC | -1.52 | -1.53 | -0.7% | 20.23 | -11.0% | -1.6% | -5.2% | -2.3% | +1.4% | +2.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.65 | $9.75 | +12.7% | +20.0% | -4.6% | -5.3% | -3.2% | -5.6% |
| Mar 6 | Morgan Stanley | Maintains | Overweight → Overweight | — | $8.72 | $8.46 | -3.0% | -0.8% | +20.0% | -4.6% | -5.3% | -3.2% |
| Feb 10 | Morgan Stanley | Maintains | Overweight → Overweight | — | $10.31 | $9.02 | -12.5% | -14.2% | -4.0% | -1.8% | -4.3% | +0.6% |
| Feb 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.31 | $9.02 | -12.5% | -14.2% | -4.0% | -1.8% | -4.3% | +0.6% |
| Feb 10 | Chardan Capital | Maintains | Buy → Buy | — | $10.31 | $9.02 | -12.5% | -14.2% | -4.0% | -1.8% | -4.3% | +0.6% |
| Feb 10 | Goldman Sachs | Maintains | Neutral → Neutral | — | $10.31 | $9.02 | -12.5% | -14.2% | -4.0% | -1.8% | -4.3% | +0.6% |
| Jan 29 | Chardan Capital | Maintains | Buy → Buy | — | $11.01 | $10.81 | -1.8% | +5.4% | -3.8% | -3.4% | +0.7% | -1.0% |
| Dec 19 | Stifel | Maintains | Buy → Buy | — | $13.51 | $13.79 | +2.1% | +8.0% | +2.6% | -4.1% | +0.8% | -2.1% |
| Dec 15 | Leerink Partners | Maintains | Outperform → Outperform | — | $13.87 | $14.37 | +3.6% | -0.3% | +2.0% | -6.7% | +2.6% | +8.0% |
| Nov 20 | Chardan Capital | Maintains | Buy → Buy | — | $10.93 | $11.18 | +2.3% | -0.5% | +8.6% | +3.6% | +10.0% | -1.4% |
| Nov 7 | RBC Capital | Maintains | Outperform → Outperform | — | $11.17 | $11.00 | -1.5% | +0.4% | -1.7% | +4.8% | +0.4% | +0.3% |
| Oct 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.69 | $10.73 | +0.4% | -1.7% | +16.3% | -0.4% | -10.3% | +3.8% |
| Sep 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.71 | $9.72 | +0.1% | -2.4% | +4.3% | -3.2% | -0.8% | -3.1% |
| Sep 8 | Chardan Capital | Maintains | Buy → Buy | — | $9.71 | $9.72 | +0.1% | -2.4% | +4.3% | -3.2% | -0.8% | -3.1% |
| Aug 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.71 | $8.26 | -5.2% | -7.8% | +0.5% | +0.5% | +11.1% | -0.4% |
| Aug 8 | RBC Capital | Maintains | Outperform → Outperform | — | $7.90 | $7.82 | -1.0% | -0.6% | -5.0% | +8.6% | +10.2% | +1.5% |
| Aug 8 | Barclays | Maintains | Overweight → Overweight | — | $7.90 | $7.82 | -1.0% | -0.6% | -5.0% | +8.6% | +10.2% | +1.5% |
| Aug 8 | Chardan Capital | Maintains | Buy → Buy | — | $7.90 | $7.82 | -1.0% | -0.6% | -5.0% | +8.6% | +10.2% | +1.5% |
| Jun 9 | Chardan Capital | Maintains | Buy → Buy | — | $9.61 | $9.87 | +2.7% | -0.8% | +2.9% | +4.0% | +0.0% | -9.1% |
| Apr 17 | Goldman Sachs | Maintains | Neutral → Neutral | — | $6.16 | $6.10 | -1.0% | -3.6% | +12.3% | +17.2% | +13.4% | +3.7% |
| Mar 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.36 | $8.22 | -1.7% | -1.4% | +5.6% | -5.6% | -0.1% | -3.5% |
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.50 | $8.37 | -1.5% | -1.6% | -1.4% | +5.6% | -5.6% | -0.1% |
| Mar 20 | Chardan Capital | Maintains | Buy → Buy | — | $8.50 | $8.37 | -1.5% | -1.6% | -1.4% | +5.6% | -5.6% | -0.1% |
| Mar 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.72 | $6.71 | -0.1% | +4.2% | +11.4% | +9.0% | -1.6% | -1.4% |
| Mar 14 | Morgan Stanley | Maintains | Overweight → Overweight | — | $6.55 | $7.07 | +7.9% | +2.6% | +4.2% | +11.4% | +9.0% | -1.6% |
| Mar 14 | Chardan Capital | Maintains | Buy → Buy | — | $6.55 | $7.07 | +7.9% | +2.6% | +4.2% | +11.4% | +9.0% | -1.6% |
| Feb 11 | Goldman Sachs | Downgrade | Buy → Neutral | — | $7.89 | $7.41 | -6.1% | -7.1% | -1.8% | +1.7% | -0.3% | +3.8% |
| Jan 21 | RBC Capital | Maintains | Outperform → Outperform | — | $7.37 | $7.41 | +0.5% | +2.7% | +3.7% | +1.3% | -0.9% | -2.7% |
| Jan 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.05 | $7.40 | +5.0% | +5.5% | -3.9% | +3.1% | +2.7% | +3.7% |
| Dec 11 | RBC Capital | Maintains | Outperform → Outperform | — | $9.76 | $9.75 | -0.1% | -4.7% | -6.2% | -5.0% | +3.1% | -0.8% |
| Nov 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.63 | $9.38 | -2.6% | -4.7% | +4.5% | -0.1% | -0.3% | +4.8% |
| Nov 20 | Chardan Capital | Maintains | Buy → Buy | — | $9.56 | $9.56 | +0.0% | +0.7% | -4.7% | +4.5% | -0.1% | -0.3% |
| Nov 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.43 | $10.20 | +8.2% | +18.7% | -0.3% | +3.6% | -9.3% | +1.7% |
| Oct 22 | Chardan Capital | Maintains | Buy → Buy | — | $10.37 | $10.27 | -1.0% | -7.5% | +1.6% | -1.6% | -2.4% | +0.3% |
| Sep 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.34 | $11.25 | -0.8% | -0.5% | +0.9% | +0.9% | -0.7% | +3.4% |
| Aug 5 | Barclays | Maintains | Overweight → Overweight | — | $13.04 | $12.29 | -5.8% | -4.1% | +1.4% | -5.1% | -1.2% | -1.8% |
| Aug 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.04 | $12.29 | -5.8% | -4.1% | +1.4% | -5.1% | -1.2% | -1.8% |
| Jun 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.21 | $12.20 | -0.1% | -2.7% | +1.2% | +6.4% | -3.7% | -6.6% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.80 | $16.28 | +3.0% | +2.7% | -1.4% | -0.1% | -0.8% | -3.4% |
| Apr 12 | Stifel | Maintains | Buy → Buy | — | $19.02 | $19.02 | +0.0% | -4.9% | -0.4% | -2.9% | -2.7% | -5.4% |
| Mar 8 | RBC Capital | Upgrade | Sector Perform → Outperform | — | $23.23 | $24.24 | +4.3% | -2.1% | +0.4% | -3.8% | +2.2% | -2.8% |
| Mar 7 | Barclays | Maintains | Overweight → Overweight | — | $24.00 | $23.38 | -2.6% | -3.2% | -2.1% | +0.4% | -3.8% | +2.2% |
| Mar 7 | Chardan Capital | Maintains | Buy → Buy | — | $24.00 | $23.38 | -2.6% | -3.2% | -2.1% | +0.4% | -3.8% | +2.2% |
| Mar 6 | Baird | Maintains | Outperform → Outperform | — | $24.61 | $26.74 | +8.7% | -2.5% | -3.2% | -2.1% | +0.4% | -3.8% |
| Mar 6 | Leerink Partners | Upgrade | Market Perform → Outperform | — | $24.61 | $26.74 | +8.7% | -2.5% | -3.2% | -2.1% | +0.4% | -3.8% |
| Feb 28 | Wedbush | Maintains | Neutral → Neutral | — | $20.02 | $19.01 | -5.0% | -0.6% | -12.4% | +21.5% | +0.8% | +15.2% |
| Feb 12 | Wedbush | Maintains | Neutral → Neutral | — | $16.21 | $16.29 | +0.5% | +7.1% | -7.6% | +4.7% | +9.9% | +2.1% |
| Oct 5 | Wedbush | Maintains | Neutral → Neutral | — | $15.16 | $15.04 | -0.8% | +4.4% | +0.4% | +1.1% | +4.7% | -0.1% |
| Oct 4 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $16.50 | $16.84 | +2.1% | -8.1% | +4.4% | +0.4% | +1.1% | +4.7% |
| Aug 29 | Morgan Stanley | Maintains | Overweight → Overweight | — | $18.41 | $18.41 | +0.0% | -0.1% | +0.2% | -3.9% | +2.4% | -3.8% |
No insider trades available.
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
Regeneron's partnership with GlaxoSmithKline could accelerate commercial reach and reduce development costs, potentially boosting near-term revenue while validating pipeline strength.
Mar 20
8-K
REGENXBIO Inc. -- 8-K Filing
RegenXBio is advancing multiple late-stage gene therapy programs targeting rare and retinal diseases, with key clinical catalysts expected throughout 2026.
Mar 5
8-K · 8.01
!! High
REGENXBIO Inc. -- 8-K 8.01: Material Event / Announcement
RegenXBio received a Complete Response Letter from the FDA regarding its RGX-121 gene therapy for Mucopolysaccharidosis type II, delaying market approval and requiring additional clinical or manufacturing data.
Feb 10
Data updated apr 26, 2026 10:41pm
· Source: massive.com